当前位置: 首页 > 期刊 > 《中国实用医药》 > 2010年第17期
编号:11935656
Th17在多发性硬化中发病机制及相关治疗进展(4)
http://www.100md.com 2010年6月15日 《中国实用医药》 2010年第17期
     [22] Martin-Saavedra FM, Gonzalez-Garcia C, Bravo B, et al. Beta interferon restricts the inflammatory potential of CD+4 cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol, 2008,45:4008-4019.

    [23] Nowak EC, Weaver CT, Turner H, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med, 2009.

    [24] Bai L, Lennon DP, Eaton V, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia, 2009,57:1192-1203.

    [25] Tsukimoto M, Nakatsukasa H, Sugawara K, et al. Repeated 0.5-Gy gamma irradiation attenuates experimental autoimmune encephalomyelitis with up-regulation of regulatory T cells and suppression of IL17 production. Radiat Res, 2008,170:429-436.

    [26] Klemann C, Raveney BJ, Klemann AK, et al. Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis. Am J Pathol, 2009,174:2234-2245., 百拇医药(瞿金涛 汪玫 肖林)
上一页1 2 3 4